Karanikola Aikaterini-Eleftheria, Soulaidopoulos Stergios, Leontsinis Ioannis, Dri Eirini, Sagris Marios, Kordalis Athanasios, Aznaouridis Konstantinos, Tsiachris Dimitrios, Tsioufis Konstantinos
First Department of Cardiology, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, Vas. Sofias 114, 11527 Athens, Greece.
Life (Basel). 2024 Dec 2;14(12):1590. doi: 10.3390/life14121590.
Patent foramen ovale (PFO) closure has proven to be an effective method of reducing the risk of recurrent stroke in patients with embolic stroke of unknown origin (ESUS). One of the most recognized post-procedural complications is the de novo occurrence of supraventricular arrhythmias, mainly atrial fibrillation, in the first three months following PFO closure. Earlier studies reported the incidence to be around 3.4-7%; however, this percentage has risen in recent studies up to 21%. The pathogenesis behind this type of arrhythmia is complex and not clearly understood, although it seems that direct effects of the device on the atria, as well as an inflammatory response, are the two most prevalent mechanisms. Management of this complication might be challenging given the heterogenicity of patient characteristics, so an individualized approach is most wisely followed. This review aims to present the current data on the incidence, pathogenesis and therapeutic strategies behind this rather common concern in an era of increasing transcatheter interventions for PFO.
卵圆孔未闭（PFO）封堵已被证明是降低不明原因栓塞性卒中（ESUS）患者复发性卒中风险的有效方法。最常见的术后并发症之一是在PFO封堵后的头三个月内新发室上性心律失常，主要是心房颤动。早期研究报告的发生率约为3.4%-7%；然而，最近的研究中这一百分比已升至21%。尽管这种心律失常背后的发病机制似乎是装置对心房的直接作用以及炎症反应这两种最常见的机制，但仍很复杂且尚未完全明确。鉴于患者特征的异质性，这种并发症的管理可能具有挑战性，因此最明智的做法是采用个体化方法。本综述旨在介绍在经导管PFO干预日益增多的时代，关于这一相当常见问题的发生率、发病机制和治疗策略的当前数据。
